Ab­b­Vie nabs sev­enth FDA ap­proval for Rin­voq, adds Crohn’s dis­ease in­di­ca­tion

Ab­b­Vie picked up an­oth­er in­di­ca­tion for block­buster Rin­voq on Thurs­day, this time for Crohn’s dis­ease. The sev­enth FDA ap­proval for the JAK in­hibitor is specif­i­cal­ly for use in mod­er­ate to se­vere Crohn’s pa­tients who have had in­ad­e­quate re­sponse or in­tol­er­ance of at least one TNF block­er.

While there are sev­er­al oth­er bi­o­log­ics al­ready on the mar­ket to treat mod­er­ate­ly to se­vere­ly ac­tive Crohn’s in­clud­ing J&J’s Ste­lara, Take­da’s En­tyvio and Ab­b­Vie’s own Skyrizi, the FDA not­ed that Rin­voq is the first oral drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER